Bioventus Inc. (BVS) Misses Q3 EPS by 9c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts BVS Hot Sheet
Join SI Premium – FREE
Bioventus Inc. (NASDAQ: BVS) reported Q3 EPS of ($0.07), $0.09 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $139 million versus the consensus estimate of $133.24 million.
GUIDANCE:
Bioventus Inc. sees FY2024 EPS of $0.40-$0.42, versus the consensus of $0.39. Bioventus Inc. sees FY2024 revenue of $562-567 million, versus the consensus of $561.7 million.
For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crude Inventory Fell 0.9 Million Barrels Last Week - EIA
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
